The deal will allow Novavax to lift its "going concern" warning, which it first issued in 2023 due to having "substantial ...
Novavax (NVAX) stock surged after reaching a licensing agreement with Sanofi (SNY) for its COVID-19 vaccine and Matrix-M adjuvant. Read more here.
(Reuters) -Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors ...
Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the ...
The COVID-19 vaccine was worth tens of billions of dollars, but most of it went into the hands of Moderna and Pfizer. Smaller ...
The vaccine maker's recovery story is looking brighter.
Shares of vaccine stocks Moderna ( MRNA 1.58%), Novavax ( NVAX 2.31%), and BioNTech SE ( BNTX -2.07%) rallied this week, ...
Novavax will only be able to offer a COVID-19 vaccine in the United States this autumn if regulators accept the shot it has ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Novavax (NASDAQ:NVAX) stock was among the laggards in the race ...
The Biden administration's new tariffs on Chinese electric vehicles and other strategic sectors aim to protect the future of ...
Novavax (NVAX) surges after one of its top shareholders drops a proxy campaign against the company. This withdrawal is in ...
Novavax (NVAX) stock as Shah Capital withdraws its proxy campaign against the company following a licensing agreement with ...